ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CMPX Compass Therapeutics Inc

1.9438
0.0838 (4.51%)
Last Updated: 15:01:49
Delayed by 15 minutes
Share Name Share Symbol Market Type
Compass Therapeutics Inc NASDAQ:CMPX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0838 4.51% 1.9438 1.94 1.95 2.02 1.88 1.91 1,158,921 15:01:49

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

02/12/2024 1:00pm

GlobeNewswire Inc.


Compass Therapeutics (NASDAQ:CMPX)
Historical Stock Chart


From Nov 2024 to Jan 2025

Click Here for more Compass Therapeutics Charts.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th Annual Healthcare Conference taking place in New York City, NY December 3-5, 2024.

Presentation detailsDate: Wednesday, December 4, 2024Time: 9:50-10:10 AM ESTWebcast Link: https://event.webcasts.com/

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contactir@compasstherapeutics.com

Media ContactAnna Gifford, Senior Manager of Communicationsmedia@compasstherapeutics.com617-500-8099

1 Year Compass Therapeutics Chart

1 Year Compass Therapeutics Chart

1 Month Compass Therapeutics Chart

1 Month Compass Therapeutics Chart

Your Recent History

Delayed Upgrade Clock